ImmunoPrecise Antibodies Ltd. Files 6-K Report
Ticker: HYFT · Form: 6-K · Filed: Jun 25, 2024 · CIK: 1715925
Sentiment: neutral
Topics: filing, press-release
TL;DR
IPA files 6-K, check their June 25th press release for news.
AI Summary
ImmunoPrecise Antibodies Ltd. filed a Form 6-K on June 25, 2024, to report a press release dated June 25, 2024. The filing does not contain specific financial figures or operational details beyond the announcement of the press release.
Why It Matters
This filing indicates that ImmunoPrecise Antibodies Ltd. has made a public announcement, which may contain material information relevant to investors.
Risk Assessment
Risk Level: low — This filing is primarily procedural, reporting the issuance of a press release without disclosing new financial or operational data within the 6-K itself.
Key Players & Entities
- ImmunoPrecise Antibodies Ltd. (company) — Registrant
- Kristin Taylor (person) — Signatory for the company
- June 25, 2024 (date) — Date of press release and filing
FAQ
What is the primary purpose of this 6-K filing?
The primary purpose of this 6-K filing is to report a press release issued by ImmunoPrecise Antibodies Ltd. on June 25, 2024.
What is the filing date of this Form 6-K?
This Form 6-K was filed on June 25, 2024.
What exhibit is included with this filing?
Exhibit 99.1, a Press Release dated June 25, 2024, is included with this filing.
Who signed this report on behalf of ImmunoPrecise Antibodies Ltd.?
Kristin Taylor signed this report on behalf of ImmunoPrecise Antibodies Ltd.
What is the principal executive office address for ImmunoPrecise Antibodies Ltd.?
The principal executive office address for ImmunoPrecise Antibodies Ltd. is 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8.
Filing Stats: 143 words · 1 min read · ~1 pages · Grade level 10.7 · Accepted 2024-06-25 09:12:15
Filing Documents
- 6k-_press_release_june_2.htm (6-K) — 21KB
- ipa-ex99_1.htm (EX-99.1) — 21KB
- 0000950170-24-077061.txt ( ) — 43KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. IMMUNOPRECISE ANTIBODIES LTD. Date: June 25, 2024 By: /s/ Kristin Taylor Name: Kristin Taylor Title: Chief Financial Officer